JP2022518778A5 - - Google Patents
Info
- Publication number
- JP2022518778A5 JP2022518778A5 JP2021543157A JP2021543157A JP2022518778A5 JP 2022518778 A5 JP2022518778 A5 JP 2022518778A5 JP 2021543157 A JP2021543157 A JP 2021543157A JP 2021543157 A JP2021543157 A JP 2021543157A JP 2022518778 A5 JP2022518778 A5 JP 2022518778A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797743P | 2019-01-28 | 2019-01-28 | |
| US62/797,743 | 2019-01-28 | ||
| US201962931502P | 2019-11-06 | 2019-11-06 | |
| US62/931,502 | 2019-11-06 | ||
| PCT/US2020/015441 WO2020160010A1 (en) | 2019-01-28 | 2020-01-28 | Compounds and methods for the treatment of cystic fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518778A JP2022518778A (ja) | 2022-03-16 |
| JP2022518778A5 true JP2022518778A5 (enExample) | 2023-02-01 |
Family
ID=71841934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543157A Pending JP2022518778A (ja) | 2019-01-28 | 2020-01-28 | 嚢胞性線維症の治療のための化合物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230055237A1 (enExample) |
| EP (1) | EP3917516A4 (enExample) |
| JP (1) | JP2022518778A (enExample) |
| CN (1) | CN113613649A (enExample) |
| WO (1) | WO2020160010A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR118050A1 (es) * | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| WO2022032062A1 (en) * | 2020-08-06 | 2022-02-10 | Carlex Glass America, Llc | Method of attaching a connector to a glazing |
| EP4029500A1 (en) * | 2021-01-15 | 2022-07-20 | Universidad Autónoma de Madrid | Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the nrf2-beta-trcp interaction for use in the treatment of nrf2-related diseases |
| RU2763141C1 (ru) * | 2021-06-29 | 2021-12-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017919B1 (ru) * | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| WO2016201440A1 (en) * | 2015-06-12 | 2016-12-15 | The Regents Of The University Of California | Spiroindolinones and therapeutic uses thereof |
| WO2017117239A1 (en) * | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
-
2020
- 2020-01-28 EP EP20747868.6A patent/EP3917516A4/en not_active Withdrawn
- 2020-01-28 JP JP2021543157A patent/JP2022518778A/ja active Pending
- 2020-01-28 CN CN202080018339.8A patent/CN113613649A/zh active Pending
- 2020-01-28 WO PCT/US2020/015441 patent/WO2020160010A1/en not_active Ceased
-
2021
- 2021-07-23 US US17/383,797 patent/US20230055237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1213033C (zh) | 二[(e)－7－[4－(4－氟苯基)－6－异丙基－2－[甲基(甲基磺酰基)氨基]嘧啶－5－基](3r,5s)－3,5－二羟基庚－6－烯酸]钙盐晶体 | |
| KR102827138B1 (ko) | 화합물 | |
| RU2010114732A (ru) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида | |
| AU2014294997B2 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| WO2018081377A1 (en) | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis | |
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| CN103827088B (zh) | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 | |
| IL273752B1 (en) | Ingredients, compounds and methods for increasing cftr activity | |
| JP2024509818A5 (enExample) | ||
| TWI908788B (zh) | α-１抗胰蛋白酶之調節劑 | |
| WO2010115836A4 (en) | Substituted piperidines as ccr3 antagonists | |
| CZ36699A3 (cs) | Muskarinní antagonisté | |
| JP2011509280A5 (enExample) | ||
| CA2143744A1 (en) | Diaryl piperazinoacetamide compounds as antimuscarinic agents | |
| JP2022518148A5 (enExample) | ||
| US20250255859A1 (en) | Methods of treating cftr-mediated diseases or disorders | |
| HRP20170572T1 (hr) | Derivati pirazina kao agonisti receptora cb2 | |
| TW200530164A (en) | Sulfonamide derivatives for the treatment of diseases | |
| CN101959855A (zh) | 氮杂环丁烷衍生化合物、其制备方法和其治疗用途 | |
| JP2018529657A5 (enExample) | ||
| JP6937524B2 (ja) | アミド化合物およびその使用 | |
| CA2598725A1 (en) | Fused aromatic compounds having anti-diabetic activity | |
| US9388166B2 (en) | 6-aminoindole derivatives as TRP channel antagonists | |
| JP2010539154A (ja) | ムスカリン様受容体アンタゴニストとして活性な新規化合物 | |
| CN102947298A (zh) | 生物碱氨基酯衍生物及其药物组合物 |